Results 31 to 40 of about 557 (132)

Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. [PDF]

Clin Pharmacokinet
Nielsen MJF, Becker NP, Duus HHH, Kirkeby K, Kupčová V, Lauenborg BW, Low B, Svolgaard O, Witten L.   +8 more
europepmc   +2 more sources

Incretin-based therapies for the treatment of obesity-related diseases

npj Metabolic Health and Disease
Obesity-related disability-adjusted life years (DALYs) are expected to increase by approximately 40% from 2020 to 2030. DALYs and mortality related to obesity are the consequence of multiple comorbidities such as cardiovascular (i.e., heart failure) and ...
Irene Caruso, Angelo Cignarelli, Gian Pio Sorice, Sebastio Perrini, Francesco Giorgino   +4 more
doaj   +2 more sources

An update on peptide-based therapies for type 2 diabetes and obesity [PDF]

, 2023
Long-acting analogues of the naturally occurring incretin, glucagon-like peptide-1 (GLP-1) and those modified to interact also with receptors for glucose-dependent insulinotropic polypeptide (GIP) have shown high glucose-lowering and weight-lowering ...
Flatt, Peter R, Conlon, J Michael, Bailey, Clifford J   +2 more
core   +1 more source

Long-acting amylin analogues for the management of obesity

, 2022
PURPOSE OF REVIEW: To summarize recent developments of long-acting amylin analogues for the treatment of obesity and to outline their mode of action. RECENT FINDINGS: Amylin is a pancreatic hormone acting to control energy homeostasis and body weight ...
Mathiesen, David S., Jonatan I. Bagger, Bagger, Jonatan I., Knop, Filip K., David S. Mathiesen, Filip K. Knop   +5 more
core   +1 more source

Incretin‐Based Therapies: A Testable Hypothesis Linking Incretin Signaling, Mitochondrial Redox, and OXPHOS Efficiency

Obesity, EarlyView.
ABSTRACT Objective Incretin‐based obesity therapies (IBTs), especially GLP‐1 receptor agonists (GLP‐1 RAs), effectively treat obesity and improve comorbidities. However, their impact on energy metabolism is unclear. A recent case of acute generalized muscle weakness in a patient with mitochondrial myopathy after tirzepatide exposure raises concerns ...
Bryn Falahee, Caroline M. Apovian, Nawfal Istfan   +2 more
wiley   +1 more source

Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis

VIEW, EarlyView.
In this systematic review and network meta‑analysis of 140 studies, anti‑obesity medications showed heterogeneous ocular safety profiles. Semaglutide was associated with higher NAION risk (observational data), whereas dual/multi‑agonists and glucagon‐like peptide‐1 receptor agonists demonstrated favourable glaucoma and overall ocular outcomes ...
Linge Jian, Keke Zhang, Wenwen He, Yan Ke, Yi Lu, Xiangjia Zhu   +5 more
wiley   +1 more source

Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness - a narrative review

, 2023
IntroductionPsychotropic medications, especially antipsychotics, have been consistently shown to cause weight gain in individuals with severe mental illness (SMI), a population inherently challenged by poor physical health.
Femin Prasad, Prasad, Femin, De, Riddhita, Riddhita De, Hahn, Margaret K., Filip K. Knop, Luisa Burin, Ebdrup, Bjørn H., Nicolette Stogios, Agarwal, Sri Mahavir, Stogios, Nicolette, Burin, Luisa, Margaret K. Hahn, Sri Mahavir Agarwal, Knop, Filip K., Bjørn H. Ebdrup   +15 more
core   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

British Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source